TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02747056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical, psychological and neuropsychological assessment
Description: the subjects will do 3 tests about executive functions, complete 3 questionnaires about autism and 3 questionnaires about the self concept

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical, psychological and neuropsychological assessment
Description: the subjects will do 3 tests about executive functions, complete 3 questionnaires about autism and 3 questionnaires about the self concept

Intervention type: OTHER
Group type: OTHER
Intervention: clinical, psychological and neuropsychological assessment
Description: the subjects will do 3 tests about executive functions, complete 3 questionnaires about autism and 3 questionnaires about the self concept

Intervention type: OTHER
Group type: OTHER
Intervention: clinical, psychological and neuropsychological assessment
Description: the subjects will do 3 tests about executive functions, complete 3 questionnaires about autism and 3 questionnaires about the self concept

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autobiographical memories Assessment
Description: The investigators will ask subjects to tell autobiographical memories freely first and, secondly, to specify participants'characteristics by answering focused questions.

Intervention type: OTHER
Group type: OTHER
Intervention: Autobiographical memories Assessment
Description: The investigators will ask subjects to tell autobiographical memories freely first and, secondly, to specify participants'characteristics by answering focused questions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autobiographical memories assessment characteristics
Description: During the second time point, the investigators will ask subjects to say the self statements which define them. Then, subjects will have to tell and to specify the characteristics of the autobiographical memories linked to these self statements.

Intervention type: OTHER
Group type: OTHER
Intervention: Autobiographical memories assessment characteristics
Description: During the second time point, the investigators will ask subjects to say the self statements which define them. Then, subjects will have to tell and to specify the characteristics of the autobiographical memories linked to these self statements.
Study: NCT02619578

Intervention type: OTHER
Group type: OTHER
Intervention: TEAS
Description: According to the theory of traditional Chinese medicine, bilateral Baihui (GV20), Yingtang (EX-HN3), Zusanli (ST36) and Neiguan (PC6) were chosen as the acupuncture points. These acupoints were identified according to the traditional anatomic localization . Gel electrodes were applied to the skin after it had been cleaned with ethyl alcohol. The acupoints were then stimulated electrically with an intensity of 12-15 mA and dense-disperse frequency of 2/100 Hz for 30 min, using the Hwato electronic acupuncture treatment instrument (model No. SDZ-V, Suzhou Medical Appliances Co., Ltd, Suzhou, China). The intensity was adjusted to maintain a slight twitching of local muscles according to individual maximum tolerance, indicating a satisfactory of De-Qi phenomenon and thus adequate stimulation.

Intervention type: OTHER
Group type: OTHER
Intervention: Con
Description: The patients in the Con group had the electrodes applied at the same acupoints, but received no stimulation.

Intervention type: DRUG
Group type: OTHER
Intervention: propofol, remifentanil, vecuronium
Description: Anesthesia was induced i.v. with propofol (2 mg kg-1) and remifentanil (1 μg kg-1) using a target-controlled infusion (TCI) system. After loss of consciousness, vecuronium (0.1 mg kg-1) was administered i.v.

Intervention type: DRUG
Group type: OTHER
Intervention: propofol, remifentanil, vecuronium
Description: Anesthesia was induced i.v. with propofol (2 mg kg-1) and remifentanil (1 μg kg-1) using a target-controlled infusion (TCI) system. After loss of consciousness, vecuronium (0.1 mg kg-1) was administered i.v.

Intervention type: OTHER
Group type: OTHER
Intervention: mechanical ventilation
Description: Patients' lungs were mechanically ventilated in a volume-controlled mode with a tidal volume of 8ml kg-1 body weight during the operation.

Intervention type: OTHER
Group type: OTHER
Intervention: mechanical ventilation
Description: Patients' lungs were mechanically ventilated in a volume-controlled mode with a tidal volume of 8ml kg-1 body weight during the operation.
Study: NCT02676778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7777
Study: NCT01280643

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA analysis
Description: Correlative studies
Study: NCT03786536

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MediSieve Magnetic Haemofiltration System
Description: The MediSieve Magnetic Haemofiltration System is a medical device intended for use in extracorporeal clinical procedures to remove magnetic targets (e.g. malaria infected red blood cells) from a patient's bloodstream.
Study: NCT04249817

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Conferencing with Exteneded Role Practitioner (VC-ERP)
Description: Participant goes to Ontario Telemedicine site for follow-up. At site, participant will get a physical assessment by an extended role practitioner and then will connect to their rheumatologist by videoconferencing for completion of follow-up.
Study: NCT01362829

Intervention type: OTHER
Intervention: Determined by intended physician
Description: We perform a prospective observational study. All the treatment for the patients are determined by intended physicians.
Study: NCT05314907

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Explanation on how to use self-sampling device and training in the screening visit.
Description: During the screening visit, woman is offered to participate in the study. If she accepts, informed consent is signed, a sociodemographic questionnaire is collected, and a cervical sample is collected for HPV detection by the health professional in the consultation.~Then, the professional informs the woman of how to carry out the self-collection using Evalyn Brush and after the woman collects an HPV sample by self-sampling in the same medical center as a trainning.~Finally, a new cervibrush (Evalyn brush) is given to the woman for home self-sampling, together with written and picture-based instructions on how to obtain the sample and an acceptability questionnaire. After one month from the screening visit, woman is requested to return the self-collected sample together with the questionnaire in person to the recruitment centre.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Only explanation on how to use self-sampling device.
Description: During the screening visit, woman is offered to participate in the study. If she accepts, informed consent is signed, a sociodemographic questionnaire is collected, and a cervical sample is taken for HPV detection by the health professional in the consultation.~Then, the professional informs the woman of how to carry out the self-collection using Evalyn.~Finally, a Evalyn brush is given to the woman for home self-sampling, together with written and picture-based instructions on how to obtain the sample and an acceptability questionnaire. After one month from the screening visit, woman is requested to return the self-collected sample together with the questionnaire in person to the recruitment centre.
Study: NCT02073682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: After the 5 day treatment with LMWH, patients receive edoxaban 60 mg once daily (QD) as 2 × 30 mg tablets (or 1 x 30 mg tablet QD for patients requiring dose adjustment) for the remainder of the treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalteparin
Description: Dalteparin was administered via subcutaneous injection at a dose of 200 IU/kg (maximum daily dose 18,000 IU) for 30 days, and at a dose of 150 IU/kg from Day 31 to the end of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Description: Therapeutic doses of subcutaneous LMWH were administered for at least 5 days (to patients in the edoxaban group); this 5-day period may have included the pre-randomization LMWH (if applicable). The choice of parenteral LMWH was up to the treating physician.
Study: NCT03077230

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre/Post Test of a Lung Cancer Screening Decision Aid
Description: After completing the baseline survey, the research team member will ask each participant asked to view the lung cancer screening decision aid on a tablet. The following areas regarding lung cancer screening: What is lung cancer?, Why is lung cancer a problem?, What is screening?, What is low-dose CT screening, Recommended frequency of screening, Screening factors, lung cancer risks and benefits (magnitude of benefit, harms, false positive, invasive procedures, radiation, stress/anxiety), Summary, Values Clarification, Screening Choice, and Smoking cessation messaging for current smokers OR positive reinforcement for former smokers.
Study: NCT00813189

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GH treatment
Description: GH treatment will be administered at a weekly dose of 0.46 mg/kg/ week, divided into seven daily subcutaneous injections. Subcutaneous injections should be given slowly, in the thigh. In order to prevent lipoatrophy, the injection site should be varied. The injection should be given at bedtime.
Study: NCT01740414

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MN-166 (50 mg) First
Description: In this arm of the study participants were first maintained on 50 mg MN-166 BID for approximately 14 days, and were then switched onto placebo maintenance. The subjective and analgesic effects of Oxycodone (0 mg, 15 mg and 30 mg) were tested under each of the two maintenance conditions (Placebo \& MN-166).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo First
Description: This arm of the study participants were first maintained on placebo for approximately 14 days, and were then switched onto 50mg MN-166 BID maintenance. . The subjective and analgesic effects of Oxycodone (0 mg, 15 mg and 30 mg) were tested under each of the two maintenance conditions (Placebo \& MN-166).
Study: NCT04475120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal lactoferrin
Description: oral and intra-nasal formulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOC therapy
Description: oral administration
Study: NCT03698227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: iv infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Description: iv infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: iv infusion
Study: NCT00913419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine HCl Tablets 10 mg, Cord Laboratories

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclobenzaprine HCl Tablets 10 mg, Merck Sharp & Dohme
Study: NCT03660761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib
Description: The patient was given a daily dose of apatinib 500mg (or based on weight). For adult, the dose of apatinib was prescribed with 425 mg or 500 mg per day and four weeks for a cycle. The dosage was modified to 250 mg if patients experienced ≧grade 2 hematologic adverse events, hand and foot syndrome, proteinuria, fecal ocular blood, or grade 3/4 hypertension, or other grade 3/4 adverse events. Apatinib was administrated until disease progression, unacceptable toxicity or death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temodar
Description: dose-dense temozolomide (100 mg/m2 , 7 days on with 7 days off ) , 28d
Study: NCT03826069

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Augmented reality-based curriculum
Description: Participants in the Augmented Reality Group will be taught principles in augmented reality and training sessions will be enhanced by an augmented reality platform. This involves training on virtual reality simulators with superimposed videos and guides demonstrating correct procedure. In this study, the videos and guides will be on identifying and removing polyps.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Simulation Curriculum
Description: Participants in this group will will train from low- to high-fidelity colonoscopy simulation. During training, the participants will receive guidance and feedback from expert endoscopists. In addition, there will be didactic sessions covering theory of colonoscopy.
Study: NCT04678635

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Chronic transcranial direct current stimulation
Description: Chronic transcranial direct current stimulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chronic transcranial direct current stimulation
Description: Chronic transcranial direct current stimulation
Study: NCT00583063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: 25 mg daily (oral dosing)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: 25 mg daily (oral dosing)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rapamycin
Description: 4 mg daily (oral dosing)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rapamycin
Description: 4 mg daily (oral dosing)
Study: NCT00752479

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells infusion, Basiliximab,Methylprednisolone,RATG ,Cyclosporine ,Mycophenolate mofetil
Description: Cell therapy~Mesenchymal cells infusion.~Induction therapy:~Basiliximab (20 mg i.v.day 0 and day 4 post-tx). Low dose RATG (0.5 mg/kg/day i.v. day 0-6 post-tx). Methylprednisolone (500 mg to 25 mg from day 0 to 6 post-tx. Then stop).~Maintenance therapy:~Cyclosporine (from day 0: dose according to target trough blood level). Mycophenolate mofetil (750 mg b.i.d. from day 1 post-tx).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab, Methylprednisolone,RATG,Cyclosporine,Mycophenolate mofetil
Description: Routine immunosuppressive therapy~Induction therapy:~Basiliximab (20 mg i.v.day 0 and day 4 post-tx). Low dose RATG (0.5 mg/kg/day i.v. day 0-6 post-tx). Methylprednisolone (500 mg to 25 mg from day 0 to 6 post-tx. Then stop).~Maintenance therapy:~Cyclosporine (from day 0: dose according to target trough blood level). Mycophenolate mofetil (750 mg b.i.d. from day 1 post-tx).
Study: NCT03782363

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CIK Dose level 1
Description: Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory at first level of dose 20.000.000 cell/kgs days 1 and 22

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CIK Dose level 2
Description: Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory at first level of dose 25.000.000 cell/kgs days 1 and 22

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CIK Dose level 3
Description: Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory at first level of dose 20.000.000 cell/kgs days 1 and 15

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CIK Dose level 4
Description: Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory at first level of dose 25.000.000 cell/kgs days 1 and 15
Study: NCT03124576

Intervention type: DEVICE
Intervention: Implantable loop recorder
Description: Continuous rhythm monitoring Medtronic
Study: NCT01280643

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA analysis
Description: Correlative studies
Study: NCT01622673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegravir 400 mg oral tablet taken with 240 mL water every 12 hours~Throughout the study, participants will continue to take raltegravir along with their other HIV medications. On the day of co-dosing and intensive pharmacokinetic (PK) sampling, raltegravir will be dosed in the morning in a fasted state in all periods.
Study: NCT03124576

Intervention type: DEVICE
Intervention: Implantable loop recorder
Description: Continuous rhythm monitoring Medtronic

Intervention type: DEVICE
Intervention: Implantable loop recorder
Description: Continuous rhythm monitoring Medtronic

Intervention type: DEVICE
Intervention: Implantable loop recorder
Description: Continuous rhythm monitoring Medtronic
Study: NCT04042961

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reactive balance training
Description: A variety of tasks will be included to induce external or internal perturbations. External perturbations will be caused by forces outside participants' control (e.g. a push or pull from the physiotherapist). Internal perturbations are when the participant fails to control the centre of mass-base of support relationship during voluntary movement; e.g., 'agility' tasks such as kicking a soccer ball. Each session will include a five-minute warm-up, at least 60 perturbations, and a five-minute cool-down. The difficulty of the task will be set such that participants will 'fail' to recover balance \~50% of the time; 'failure' is defined as use of an upper extremity response, use of external assistance (i.e. from the overhead harness or physiotherapist), or taking more than 2 steps to regain stability. Training tasks will progressed by increasing the perturbation magnitude, including cognitive or movement tasks, or imposing sensory or environmental challenges (e.g. eyes closed, obstacles).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic and strength training (AST)
Description: AST sessions will consist of 30 minutes of aerobic and 30 minutes of strength training.~Aerobic training: Aerobic training will be done using treadmill walking or combination of modalities (e.g. cycling or recumbent stepping) for those unable to maintain the target heart rate with walking. The heart rate that occurred at the ventilatory threshold (V̇O2VT) during the cardiopulmonary exercise test will be used to prescribe intensity. In the absence of a discernible V̇O2VT a combination of the following will be used: 60-80% of heart rate reserve, peak oxygen uptake, and rating of perceived exertion of 11-16 (Borg 6-20 scale). Prescriptions will be initially progressed by increasing duration to ≥20 minutes and then increasing intensity to target heart rate.~Resistance training: Participants will be prescribed 1-2 sets of 8 exercises per session (squat, heel raise, ankle dorsiflexion, knee extension and flexion, abdominal curl-up, wall push up, bicep curl), at 70% of 1 repetition maximum.
Study: NCT01979952

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: twice daily dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: gelating capsule
Study: NCT03502447

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TearCare
Description: TearCare treatment includes an in-office 15 minute thermal treatment session where heat is delivered to the eyelids. This is immediately followed by manual clearing of the meibomian glands.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Warm Compress and Lid Massage
Description: Subjects randomized to the Warm Compress and Lid Massage Group will be instructed to apply a moist, warm compress to their eyelids daily for 5 minutes and then perform lid massage.
Study: NCT03793361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Oral Drug in the form of 40 mg tablets - Regorafenib (120 mg/d) once daily for 3 weeks on / 1 week off plus Best Supportive Care (BSC) until progression (according to RECIST 1.1), intolerance or consent withdrawal.~Provided by BAYER